Replies to post #3998643 on BB's Stock Haven

[cjstocksup]

OWCP .043 Watch the interview on the link http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125510846

OWCP one of only 2 companies taking a clinical approach with MJ research

When it comes to medical cannabis, OWC believes in science instead of mythology.

We aim to produce pharmaceutical-grade cannabis-based products and treatments that are:-

Standardized in composition, formulation and dose;
Administered by means of the appropriate and efficient innovative delivery systems; and –
Tested in properly controlled pre-clinical and clinical studies.
We believe that its planned products will provide physicians with the ability to control and administrate.

To date, One World Cannabis has signed three research collaboration agreements with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East. Within the framework of these agreements, the company will initiate pre-clinical and clinical studies to explore the effect of several combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma (a cancer of plasma cells), psoriasis and fibromyalgia.

At present, One World Cannabis is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.

One World Cannabis will continue to collaborate with other industry partners, as well as leading academic medical centers, in order to develop, clinically research, produce, and commercialized novel cannabinoid-based therapies targeting a variety of different indications and effectively help patients in need.

Upon the successful completion of clinical trials and the development of appropriate dosing forms and delivery systems for pharmaceutical-grade cannabis-based preparations, One World cannabis will determine which markets and distribution channels are most suitable for any given product or formulation. In all cases, the Company will retain the intellectual property rights to proprietary discoveries made in conjunction with its initiatives and seek to secure patent protections.